AKTS
Aktis Oncology, Inc.
Key Financials
Revenue
$6.6M
N/A
EPS (Diluted)
$-0.82
N/A
Total Assets
$557.6M
N/A
Total Liabilities
$72.8M
N/A
Net Income
$-42469000
N/A
Operating Income
$-51605000
N/A
Cash & Equivalents
$82.5M
N/A
Shareholders' Equity
$484.8M
N/A
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 9/24/2026 | View on SEC |
| 144 | 9/23/2026 | View on SEC |
| 10-Q | 8/13/2026 | View on SEC |
| 8-K | 8/13/2026 | View on SEC |
| 4 | 7/21/2026 | View on SEC |
| 4 | 7/20/2026 | View on SEC |
| 144 | 7/20/2026 | View on SEC |
| 144 | 7/17/2026 | View on SEC |
| 4 | 7/10/2026 | View on SEC |
| 4 | 7/10/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | AKTS |
| Company Name | Aktis Oncology, Inc. |
| CIK | 2035832 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 978-237-4380 |